Wordt geladen...
Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
BACKGROUND: Temsirolimus was approved in Europe as first-line treatment of poor-prognosis advanced renal cell carcinoma (advRCC) based on significant clinical benefits. METHODS: Patients with advRCC and multiple poor-prognostic factors were randomly assigned to receive 25 mg intravenous temsirolimus...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2869160/ https://ncbi.nlm.nih.gov/pubmed/20461090 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605647 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|